Experimental: Dose Arm 1
Subjects with chronic kidney disease will receive allogeneic adipose tissue-derived mesenchymal stem cells (MSC) in two intravenous infusions of 75×10^6 cells at day 0 and month 3.
Drug: Allogeneic adipose-derived mesenchymal stem cells (MSC)-Two Infusions
Two MSC infusions of 75×10^6 cells at time zero and three months; intravenous delivery
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.